ClinicalTrials.gg
TerminatedNCT02441517Updated Apr 19, 2018Results posted

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

A Phase 4 interventional study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer, sponsored by Astellas Pharma Global Development, Inc.. Terminated at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-19.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Why this study was terminated
The study is closed early due to lck of enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Neoplasm Metastasis by Astellas Pharma Inc — 4 open to participants now, 4 under way, none of them phase 3. Neoplasm Metastasis · Astellas Pharma Inc.

Enrollment
14th of 15
4 · median 95
Started
2015
the only one that year
Phase 4
Only one
of the 15
Registered
7th of 15
by date

Among the 15 studies in Neoplasm Metastasis by Astellas Pharma Inc, this one is the 14th largest by enrollment, is the only one that started in 2015, is the only one in phase 4, and was the 7th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

4 of the 15 studies in Neoplasm Metastasis by Astellas Pharma Inc are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Neoplasm Metastasis by Astellas Pharma Inc, or all of them as a file.
02

Study summary

The purpose of the study was to understand if there is benefit in treatment with a medicine called enzalutamide in the re-treatment setting. Patients must have been previously treated with enzalutamide in the pre-chemotherapy setting for a minimum of 8 months and have disease progressed, followed by docetaxel and/or cabazitaxel for at least 4 cycles.

Read the detailed description

Participants received treatment with open-label enzalutamide, until radiographic or clinical progression (such as pathological fracture, cord compression, worsened pain requiring radiation therapy, or opioid analgesic dose increase or initiation), or unacceptable toxicity. Participants were to be allowed to continue enzalutamide until the next treatment was initiated. If another non-cytotoxic, non-investigational, antineoplastic agent was initiated after protocol-defined progression had been determined, enzalutamide was to be continued as long as the participant was tolerating enzalutamide and continued androgen deprivation therapy. Participants were to have a safety follow-up visit approximately 30 days following the last dose of study drug or prior to the initiation of a subsequent anti-cancer drug or investigational agent, whichever occurred first. Disease progression and survival were to be followed every 12 weeks for a maximum of 3 years from first dose. The study should have ended when the last participant has been followed for 1 year from the date of first dose, but the study was terminated and results up to the last date of evaluation (15 March 2017) are reflected in this disclosure.

03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer

Keywords

  • Xtandi
  • Metastatic Castration Resistant Prostate Cancer
  • Metastatic
  • Prostate Cancer
  • Chemotherapy
  • Castration-resistant
  • Enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without signet ring cell features.
  • Presence of disease (M1) as assessed by computed tomography/ magnetic resonance imaging (CT/MRI) and/or whole-body radionuclide bone scan.
  • Subject has been previously treated with enzalutamide for at least 8 months, and stopped enzalutamide due to progressive disease (not due to adverse events), followed by at least 4 cycles of docetaxel and/or cabazitaxel chemotherapy, with or without other intervening anti-cancer therapies (including but not limited to aminoglutethimide, ketoconozole, abiraterone acetate, Rad-223, or sipuleucel-T), prior to receiving chemotherapy. Note: for patients who receive sequential taxanes, there must not have been progressive disease upon ending the first taxane, or use of any anti-cancer agents between the two taxanes.
  • Ongoing androgen deprivation therapy with an gonadotropin releasing hormone (GnRH) analogue or prior bilateral orchiectomy (medical or surgical castration). For patients who have not had bilateral orchiectomy, there must be a plan to maintain effective GnRH-analogue for the duration of the trial.
  • Testosterone ≤ 1.73 nmol/L (≤ 50 ng/dL) at screening.
  • (ECOG) performance status of 0-2 at screening.
  • Estimated of ≥ 6 months at screening.
  • Ability to swallow study drugs and to comply with study requirements throughout the study.
  • Throughout study, male subject and a female partner who is of must use 2 acceptable methods of (1 of which must include a condom barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following:

    • Condom (barrier method of contraception) AND
    • One of the following is required:
    • Established use of oral, injected, or implanted hormonal method of contraception by the female partner performed at least 6 months before screening;
    • Placement of an intrauterine device or intrauterine system by the female partner;
    • Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner;
    • Tubal ligation in the female partner.
    • Vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy), performed at least 6 months before screening
  • Must not donate sperm from screening through 3 months after final study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected neuroendocrine/small cell feature.
  • Use of any antineoplastic treatment post-chemotherapy, including but not limited to aminoglutethimide, ketoconozole, abiraterone acetate, Rad-223, sipuleucel-T, or enzalutamide. Continuing is permitted.
  • Palliative radiation therapy within 2 weeks of Day 1, or within 4 weeks of Day 1 if a radionuclide was utilized.
  • Use of an agent within 4 weeks of Day 1 visit.
  • Major surgery within 4 weeks prior to Day 1 visit.
  • History of seizure or any condition that may predispose to seizures (e.g., prior cortical stroke or significant brain trauma) at any time in the past. History of loss of consciousness or within 12 months of screening.
  • History of cardiovascular disease including:

    • Myocardial infarction or uncontrolled angina within 3 months;
    • History of congestive heart failure (NYHA) class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan performed within three months results in a that is ≥ 45%;
    • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place.
  • Clinically significant cardiovascular disease at screening including:

    • Hypotension as indicated by systolic blood pressure \< 86 millimeters of mercury (mm Hg) at screening;
    • Bradycardia as indicated by a heart rate of \< 45 beats per minute on the screening (ECG) and on physical examination;
    • Uncontrolled hypertension as indicated by at least 2 consecutive measurements of a resting systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at the screening visit.
  • Subject has a known or suspected to enzalutamide or any components of the formulation used.
  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
  • Known or suspected or .
  • Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months).
  • \< 1,500/μL, count \< 75,000/μL, or \< 5.6 mmol/L (9 g/dL) at screening.
  • Total or (ALT) or aspartate aminotransferase (AST) ≥ 2.5 times (ULN) at screening.
  • Creatinine > 177 μmol/L (> 2 mg/dL) at screening.
  • Albumin \< 30 g/L (3.0 g/dL) at screening.
  • Treatment with abiraterone acetate prior to enzalutamide for castration - resistant prostate cancer (mCRPC) in the prechemotherapy setting. (Note: Patients who have received concomitant enzalutamide and abiraterone acetate therapies are not excluded).
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.

    Drug: Enzalutamide

Interventions

  • Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.

    Also known as: ASP9785, Xtandi, MDV3100

06

What researchers measure

Primary outcomes

  1. Radiographic Progression Free Survival (rPFS)

    Radiographic PFS (rPFS) was defined as the time from first dose to the radiographic disease progression (PD), or death on study, whichever occurred first. Radiological PD was defined by either soft tissue tumor progression defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, or bone progression defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2). Bone progression per PCWG2 was defined as a minimum of two new lesions. Progression on bone scans at time points before or at week 9 required a confirmatory scan performed six or more weeks later, where it should have demonstrated at least 2 additional new lesions (PCWG2) compared to the week 9 scan. rPFS was analyzed using Kaplan-Meier methodology to account for censored outcomes (i.e., no observation of rPFS event within the study follow-up period).

    Time frame: From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) was defined as the date of death due to any cause minus the date of first dose + 1.

    Time frame: From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)

  2. Time to Prostate-Specific Antigen (PSA) Progression

    The time to PSA progression was defined as the PSA progression date minus the date of first dose + 1. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir (lowest PSA value observed postbaseline or the baseline value for participants who did not have a decline in PSA postbaseline values) in PSA levels, and which was confirmed by a second consecutive value obtained at least 3 or more weeks later (i.e., a confirmed rising trend) (PCWG2 criteria). The date of PSA progression was the first date the PSA progression was observed. Time to PSA progression was estimated via Kaplan-Meier methodology with censoring defined by the time of the last available PSA measure.

    Time frame: From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)

  3. Number of Participants With PSA Response

    PSA response was defined for the three following categories: PSA30 response: a maximum decline of ≥ 30% from baseline at any post baseline time point; PSA50 response: a maximum decline of ≥ 50% from baseline at any post baseline time point; PSA90 response: a maximum decline of ≥ 90% from baseline at any post baseline time point.

    Time frame: From baseline up to date of last evaluation of 15 March 2017 (approximately 17 months)

  4. Number of Participants With Objective Response

    Objective response was defined as the best overall response of complete response (CR) or partial response (PR) per RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)

  5. Time to First Use of a Subsequent Antineoplastic Therapy

    Time to start of other antineoplastic therapy was defined as the date of the first systemic antineoplastic therapy minus the date of the first dose of study drug + 1.

    Time frame: From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)

  6. Number of Participants With Adverse Events

    Safety was assessed by adverse events (AEs), which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE (SAE) was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. Disease progression was not to be reported as an AE, and clinical signs and symptoms due to disease progression were collected as AEs.

    Time frame: From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)

07

Results

Posted Apr 19, 2018

Participant flow

Male participants from the United States were enrolled in this study.

Participant flow — Overall Study
MilestoneEnzalutamide
Started4
Received treatment4
Completed0
Not completed4
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2
Withdrew: Study terminated by sponsor1

Outcome measures

PrimaryRadiographic Progression Free Survival (rPFS)

Radiographic PFS (rPFS) was defined as the time from first dose to the radiographic disease progression (PD), or death on study, whichever occurred first. Radiological PD was defined by either soft tissue tumor progression defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, or bone progression defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2). Bone progression per PCWG2 was defined as a minimum of two new lesions. Progression on bone scans at time points before or at week 9 required a confirmatory scan performed six or more weeks later, where it should have demonstrated at least 2 additional new lesions (PCWG2) compared to the week 9 scan. rPFS was analyzed using Kaplan-Meier methodology to account for censored outcomes (i.e., no observation of rPFS event within the study follow-up period).

Time frame:
From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)
Reported as:
Median · days
Radiographic Progression Free Survival (rPFS)
daysEnzalutamide
Radiographic Progression Free Survival (rPFS)115 (57 to 173)
SecondaryOverall Survival

Overall survival (OS) was defined as the date of death due to any cause minus the date of first dose + 1.

Time frame:
From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)

No measurements were reported for this outcome.

SecondaryTime to Prostate-Specific Antigen (PSA) Progression

The time to PSA progression was defined as the PSA progression date minus the date of first dose + 1. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir (lowest PSA value observed postbaseline or the baseline value for participants who did not have a decline in PSA postbaseline values) in PSA levels, and which was confirmed by a second consecutive value obtained at least 3 or more weeks later (i.e., a confirmed rising trend) (PCWG2 criteria). The date of PSA progression was the first date the PSA progression was observed. Time to PSA progression was estimated via Kaplan-Meier methodology with censoring defined by the time of the last available PSA measure.

Time frame:
From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)
Reported as:
Median · days
Time to Prostate-Specific Antigen (PSA) Progression
daysEnzalutamide
Time to Prostate-Specific Antigen (PSA) Progression82.5 (1 to 142)
SecondaryNumber of Participants With PSA Response

PSA response was defined for the three following categories: PSA30 response: a maximum decline of ≥ 30% from baseline at any post baseline time point; PSA50 response: a maximum decline of ≥ 50% from baseline at any post baseline time point; PSA90 response: a maximum decline of ≥ 90% from baseline at any post baseline time point.

Time frame:
From baseline up to date of last evaluation of 15 March 2017 (approximately 17 months)
Reported as:
Number · Participants
Number of Participants With PSA Response
ParticipantsEnzalutamide
PSA30 Response2
PSA50 Response2
PSA90 Response0
SecondaryNumber of Participants With Objective Response

Objective response was defined as the best overall response of complete response (CR) or partial response (PR) per RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)
Reported as:
Count of participants · Participants
Number of Participants With Objective Response
ParticipantsEnzalutamide
Complete Response0
Partial Response0
SecondaryTime to First Use of a Subsequent Antineoplastic Therapy

Time to start of other antineoplastic therapy was defined as the date of the first systemic antineoplastic therapy minus the date of the first dose of study drug + 1.

Time frame:
From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)
Reported as:
Median · days
Time to First Use of a Subsequent Antineoplastic Therapy
daysEnzalutamide
Time to First Use of a Subsequent Antineoplastic Therapy175 (NA to NA)
SecondaryNumber of Participants With Adverse Events

Safety was assessed by adverse events (AEs), which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE (SAE) was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. Disease progression was not to be reported as an AE, and clinical signs and symptoms due to disease progression were collected as AEs.

Time frame:
From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsEnzalutamide
Any TEAE4
Drug-related TEAEs3
Deaths0
SAEs0
Drug-related SAEs0
Deaths Resulting from TEAEs0
TEAEs Leading to Permanent Discontinuation0
Drug-related TEAEs Leading to Permanent Discont.0

Adverse events

Collected over From first dose of study drug up to date of last evaluation of 15 March 2017 (approximately 17 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventEnzalutamide
FatigueGeneral disorders3/4
Oedema peripheralGeneral disorders2/4
Decreased appetiteMetabolism and nutrition disorders2/4
AstheniaGeneral disorders1/4
ArthralgiaMusculoskeletal and connective tissue disorders1/4
Back painMusculoskeletal and connective tissue disorders1/4
Bone painMusculoskeletal and connective tissue disorders1/4
Musculoskeletal painMusculoskeletal and connective tissue disorders1/4
Pain in extremityMusculoskeletal and connective tissue disorders1/4
HypokalaemiaMetabolism and nutrition disorders1/4

Baseline characteristics

The analysis population was the safety analysis set (SAF), which consisted of all participants who took at least one dose of study medication.

Age, Categorical
Age, Categorical(Participants)Enzalutamide
<=18 years0
Between 18 and 65 years0
>=65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide
Female0
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enzalutamide
Hispanic or Latino1
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enzalutamide
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported0
Any Prior Radiotherapy
Any Prior Radiotherapy(Participants)Enzalutamide
Yes2
No2
Any Prior Disease-Related Surgeries
Any Prior Disease-Related Surgeries(Participants)Enzalutamide
Yes2
No2
08

Study locations

5 sites
  • Site US10003
    Evanston, Illinois 60201, United States
  • Site US10006
    Worcester, Massachusetts 01605, United States
  • Site US10004
    New York, New York 10029, United States
  • Site US10001
    Charleston, South Carolina 29425, United States
  • Site US10002
    Myrtle Beach, South Carolina 29572, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Mar 2017, 16 months.

Results were first posted in Apr 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2015
First posted
May 12, 2015
StartActual
Oct 28, 2015
Primary completionActual
Mar 15, 2017
CompletionActual
Mar 15, 2017
Results first posted
Apr 19, 2018
Last update
Apr 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02441517
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
May 12, 2015
Start date
Oct 28, 2015
Primary completion
Mar 15, 2017
Completion
Mar 15, 2017
Results posted
Apr 19, 2018
Last update
Apr 19, 2018

Study contacts

Medical Director, Oncology
study director · APGD, Medical Affairs, Americas

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion